N/A
Completed N=4,695
Myocardial Injury and Major Adverse Outcomes in Patients With COVID-19
COVID · Myocardial Reperfusion Injury · Cardiovascular Disease
Source: ClinicalTrials.gov NCT04397939 ↗
Enrolled (actual)
4,695
Serious AEs
—
Results posted
Mar 2024
Primary outcomePrimary: Number of Death — 417; 137; 552 Participants
Summary
The study will analyze the incidence, clinical outcomes and predictors of myocardial injury in a large patient population with COVID-19 treated in Mount Sinai Hospital (MSH) system. In addition, the study team will explore the association between high-sensitivity troponin I (TnI) levels and clinical characteristics, biomarkers, cardiac tests data and treatment approaches to uncover the potential mechanisms responsible for COVID-19 induced myocardial injury.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Death |
417; 137; 552 | — |
| SECONDARY Number of Participants With Pulmonary Embolism |
32; 4; 22 | — |
| SECONDARY Number of Participants With Acute Kidney Injury |
99; 30; 107 | — |
| SECONDARY Number of Admissions to the Intensive Care |
393; 64; 325 | — |
Eligibility Criteria
Inclusion Criteria
- Laboratory confirmed COVID-19
Exclusion Criteria
- None
Data sourced from ClinicalTrials.gov (NCT04397939). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.